Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells
about
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic AgentsCholine metabolism-based molecular diagnosis of cancer: an updateROS homeostasis and metabolism: a critical liaison for cancer therapyDynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro dataImmunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolismEffects of lovastatin on breast cancer cells: a proteo-metabonomic study.Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cellsEffect of dietary sodium restriction on human urinary metabolomic profiles.Glycolysis inhibitor screening identifies the bis-geranylacylphloroglucinol protonophore moronone from Moronobea coccinea.Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.Phosphorylation of serine palmitoyltransferase long chain-1 (SPTLC1) on tyrosine 164 inhibits its activity and promotes cell survival.Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells.ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.Chronic myeloid leukemia stem cells and developing therapies.Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma.Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia.Ameliorating effect of Kalpaamruthaa on altered energy metabolism in BCR-ABL(+) cell line induced leukemic mouse model.Triomics Analysis of Imatinib-Treated Myeloma Cells Connects Kinase Inhibition to RNA Processing and Decreased Lipid Biosynthesis.The unfolded protein response in glioblastomas: targetable or trouble?Exploring cancer metabolism using stable isotope-resolved metabolomics (SIRM).S6K1 determines the metabolic requirements for BCR-ABL survival.Bezielle (BZL101)-induced oxidative stress damage followed by redistribution of metabolic fluxes in breast cancer cells: a combined proteomic and metabolomic study.Metabolic assessment of a novel chronic myelogenous leukemic cell line and an imatinib resistant subline by H NMR spectroscopy.Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production.Quantitative- and phospho-proteomic analysis of the yeast response to the tyrosine kinase inhibitor imatinib to pharmacoproteomics-guided drug line extension.Association of DJ-1/PTEN/AKT- and ASK1/p38-mediated cell signalling with ischaemic cardiomyopathy.Investigations on the cell metabolomics basis of multidrug resistance from tumor cells by ultra-performance liquid chromatography-mass spectrometry.NMR-Based Metabolomic Analysis of Normal and Inflamed Gut.Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML).
P2860
Q26740567-51768939-94B7-4807-AD52-273C957FDC4AQ27024079-31EDD4C3-2A70-4FFF-8FBD-355F9E292DF3Q28080316-97697557-0F90-4E32-93F8-4FC3076121B9Q28478542-78D980A3-7DBB-4554-93B4-436B30BCF149Q33738391-9B170A51-BFFA-4445-B91C-75FE82FF0C96Q33889477-AB4AE31C-3E60-4CFC-8812-41A82F674E3EQ33971155-E1451C17-638A-4B4A-B480-515D4D952490Q34988108-F38DE232-4085-421C-91F7-B62D015A4B73Q35817074-5771215B-DC83-457E-B05B-BB617FDD38F1Q36494623-07D4F5DE-5C6C-47B0-A0BB-D88B5586262BQ36903072-7847FE85-BE06-4682-A851-30DB3E4B3CA6Q36928954-967C72E1-D331-41C3-A4FD-6734914150F7Q37161696-76193799-13C5-4A56-8825-C74F0F3AAE23Q37379680-F85EC312-7066-4C90-B2A9-588663EFD95DQ37400663-377A7AA9-F724-42CD-971A-4D394DC9C14DQ37836936-6389247E-6B25-4DDA-A0F6-7562D38E9B73Q37871191-0CF72314-7501-4582-9A01-21FB34806BC6Q38707129-F806594C-60EA-49CA-99BE-58686C0D5880Q38761736-3AF28875-F362-489B-8219-43F0D9104378Q38762570-D0F25EEB-7E3C-419D-8861-F84418C2D551Q38830422-16628AE6-6062-44AA-B2EC-5C4E8E736BBFQ38970037-61C2A52B-DCA6-4019-9E97-85702C0F7D8CQ39358317-7D83CAB5-0D98-4D49-A583-7EEE5EEBFC75Q39385165-438164F8-3288-4375-B8DC-994A0D642170Q39555290-C37DAFCE-51BA-466D-A959-916DFED38C1DQ39672888-653A99B7-265E-494D-AF9A-AE6B0EE1D50EQ40015371-EE367282-0412-4295-B6D6-D3673195FFA2Q42586969-ABB44152-375C-45CF-A816-12F6D35BE8B1Q46634695-AC8412AF-15D3-41E5-9D68-3499B1DA2D95Q51662791-97F1A5C3-8FA9-4F6F-8D82-F154C7CDCF2CQ53091002-0E8A347B-BDED-4D36-808C-BF98147B6479Q54229178-34C0A638-0006-4420-B89F-BF5B77B20CB7
P2860
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells
@en
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.
@nl
type
label
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells
@en
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.
@nl
prefLabel
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells
@en
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.
@nl
P2093
P2860
P1476
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells
@en
P2093
Dieter Leibfritz
Douglas J Kominsky
Jaimi L Brown
Jelena Klawitter
Jost Klawitter
Junia V Melo
Natalie J Serkova
S Gail Eckhardt
Uwe Christians
P2860
P304
P356
10.1111/J.1476-5381.2009.00345.X
P407
P577
2009-08-06T00:00:00Z